Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041938 · ClinicalTrials.gov registry record · Phase 3
Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial
A Phase 3 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,305
- Enrollment target
NCT00041938 is a Phase 3 study that has completed, run by Columbia University. The registered enrollment target is 2,305 participants.
The verdict
NCT00041938, a Phase 3 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,305 participants
- Enrollment target
Study Summary
The purpose of this study is to determine which of two treatments, Warfarin or aspirin, is better for preventing death and stroke in patients with poor heart function. We are now transitioning into the sub-analysis part of the WARCEF patient data. The study has recently completed data analysis for its Primary Aim. All randomized patients have completed their follow up. All study related procedure as per the protocol has been completed. We are now in the extension phase of the study to obtain more patient data to address further aims of the study. No new procedures are performed and data already in place at the sites will be collected (EKG and echocardiograms). The aims for this study extension are: * To assess progression of cardiac dysfunction over time among heart failure patients * To correlate prognosis with cardiac dysfunction
Interventions
- DRUG Warfarin
- DRUG aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,305 participants |
| Start Date | 2002-10 |
| Est. Completion | 2014-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00041938
The ClinicalTrials.gov registry entry for NCT00041938 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,305 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT00041938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00041938 about?
NCT00041938 is a clinical study titled "Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial". The purpose of this study is to determine which of two treatments, Warfarin or aspirin, is better for preventing death and stroke in patients with poor heart function. We are now transitioning into the sub-analysis part of the WARCEF patient data. The study has recently completed data analysis for...
What is the current status of trial NCT00041938?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,305 participants. The study started on 2002-10. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00041938?
The interventions under investigation include: Warfarin (DRUG), aspirin (DRUG).
Who is sponsoring clinical trial NCT00041938?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.